Welcome to our dedicated page for Encompass Health SEC filings (Ticker: EHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Encompass Health Corporation filings document the operating results, financing arrangements and governance matters of a public inpatient rehabilitation hospital company. Its Form 8-K reports furnish earnings releases, Regulation FD materials, same-store performance measures and non-GAAP metrics such as adjusted earnings per share, leverage ratio, Adjusted EBITDA and adjusted free cash flow.
Other filings record capital-structure and governance subjects, including the company's credit agreement, revolving credit facility, subsidiary guarantor arrangements, board appointments, committee assignments and director compensation practices. The definitive proxy statement addresses annual meeting proposals, executive compensation, pay-versus-performance disclosure, board structure and stockholder voting matters.
Encompass Health Corp reported that President and CEO Mark J. Tarr acquired company stock through equity awards, rather than open-market purchases. On February 19, 2026, he received 12,796 shares of Encompass Health common stock at $0.00 per share, increasing his direct holdings to 490,812 shares. This issuance of restricted stock resulted from meeting performance criteria under a performance share unit award granted on February 23, 2023.
On February 18, 2026, Tarr was also granted 100,946 shares of restricted stock at $0.00 per share, bringing his direct ownership to 478,016 shares immediately after that grant. This award was an annual restricted stock grant made under the corporation's 2025 Omnibus Performance Incentive Plan.
Encompass Health Corp senior vice president and treasurer Edmund Fay reported equity awards of company common stock. On February 18, 2026, he acquired 7,690 shares of restricted stock at $0.00 per share as a grant or award. On February 19, 2026, he acquired an additional 1,430 restricted shares at $0.00 per share.
The filing notes that 1,430 shares were issued upon satisfaction of performance criteria from a performance share unit award granted on February 23, 2023. The 7,690-share transaction is described as an annual restricted stock award under the corporation's 2025 Omnibus Performance Incentive Plan. After these transactions, Fay directly owned over one hundred thousand Encompass Health common shares.
Encompass Health Corp executive Patrick William Tuer, EVP and Chief Operating Officer, reported acquiring company stock through equity awards. On February 18, 2026, he received 10,254 shares of Encompass Health common stock at a price of $0.00 per share as a grant or award, bringing his direct holdings to 26,296 shares.
On February 19, 2026, he received an additional 3,790 restricted shares at $0.00 per share, increasing his direct ownership to 30,086 shares. Footnotes state that one issuance reflects satisfaction of performance criteria from a February 23, 2023 performance share unit award, and the other is an annual restricted stock award under the 2025 Omnibus Performance Incentive Plan.
Encompass Health Corp. President & CEO Mark J. Tarr, who is also a director, reported multiple open-market sales of company common stock on February 11, 2026.
He sold a total of 150,000 shares at weighted-average prices ranging from $107.47 to $113.58 per share, and directly owned 377,070 shares of Encompass Health common stock after these transactions.
Invesco Ltd. has reported a significant shareholding in Encompass Health Corp. As of 12/31/2025, Invesco, as a parent holding company to its investment advisers, may be deemed to beneficially own 4,972,725 shares of Encompass Health common stock, representing 4.9% of the class.
Invesco has sole voting power over 4,761,846 shares and sole dispositive power over 4,972,725 shares, with no shared voting or dispositive power. The shares are held of record by clients of Invesco’s advisers, and no single individual has more than 5% economic ownership.
Invesco certifies that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Encompass Health, consistent with a passive investment reported on a Schedule 13G/A.
Encompass Health Corporation has a planned sale of restricted or control securities under Rule 144. The notice covers up to 150000 shares of common stock, with an aggregate market value of 16738961, to be sold through UBS Financial Services Inc. on the NYSE.
The filing states that 100615977 shares of the issuer’s common stock are outstanding. It also shows an acquisition entry where common stock was acquired on 02/17/2020 via RSA vesting from Encompass Health Corporation, with 2514 securities in that transaction.
Encompass Health Corp. executive vice president and chief operating officer Patrick William Tuer sold 2,804 shares of Encompass Health common stock in an open market transaction on February 10, 2026. The shares were sold at a weighted average price of $107.62 per share, in multiple trades ranging from $107.55 to $107.73. Following this sale, Tuer directly beneficially owns 16,042 shares of Encompass Health common stock.
Encompass Health Corporation has a shareholder filing a notice to sell 2,804 shares of its common stock under Rule 144. The planned sale through UBS Financial Services Inc. is listed with an aggregate market value of 301755, with trading on the NYSE around 02/10/2026.
The shares to be sold were acquired from Encompass Health Corporation through restricted stock unit vesting on 02/23/2024 and 02/24/2024, and performance stock unit vesting on 01/01/2025. Shares outstanding were 100,615,977 common shares at the time referenced.
Encompass Health Corporation filed a Form 8‑K to furnish its financial results for the three months and year ended December 31, 2025, as disclosed in a press release (Exhibit 99.1) and supplemental earnings materials (Exhibit 99.2).
The company explains its use of same‑store comparisons, which include hospitals open in both periods and incorporate market consolidations and capacity expansions where isolating incremental impact is difficult. It also highlights several non‑GAAP measures: adjusted earnings per share, Adjusted EBITDA, leverage ratio, and adjusted free cash flow.
Encompass Health describes how Adjusted EBITDA and its leverage ratio are central to covenants in its credit agreement, affecting the ability to incur debt, pay dividends, and make certain investments. The filing also outlines the company’s definition of adjusted free cash flow and includes extensive cautionary language about forward‑looking statements tied to its strategy, growth targets, capital plans, and financial outlook.
Encompass Health Corporation reported that its Board of Directors elected Cain A. Hayes as a director on January 30, 2026, following a recommendation from its Nominating/Corporate Governance Committee. The Board has determined that Mr. Hayes is independent under New York Stock Exchange listing standards and the company’s Corporate Governance Guidelines.
Mr. Hayes will receive compensation consistent with the company’s standard practices for nonemployee directors, as described in its April 1, 2025 proxy statement. The company stated there are no arrangements or understandings with other persons related to his selection and no related party transactions involving him that require disclosure. A press release dated February 2, 2026, announcing his election, is included as an exhibit.